Treatment of BPH with transurethral electrovaporization of the prostate (TUVP) using vaportrode VE-B. Two years follow-up.

M. Diana, M. Schettini, M. Gallucci

Research output: Contribution to journalArticle


The Authors report their experience on trasurethral vaporization of the prostate with Vaportrode for the treatment of BPH. In January 1996 we treated 24 patients suffering from cervico-urethral obstruction caused by BPH with electrovaporization of the prostate using a cutting current of between 180 and 250 Watts (average 200 Watts). Exclusion criteria was: PSA > 3 ng/ml. The catheter was removed after 24 hours. Follow-up of all patients is 27 months. 23 patients were evaluated. Results at follow-up were: mean maximum flow (Qmax) 9.31 ml/sec preoperative was 19.5 ml/sec after 6 months, 18.3 after 12 months and 18.0 after 24 months; mean symptom score decreased from 18.1 to 10.4 after 6 months, to 3.2 after 12 months and to 4.8 after 24 months; QL index decreased from 4.6 to 2.3 at 6 months, to 1.4 after 12 months and 24 months; the average voiding pressure decreased from 62.8 cm/H20 to 23.2 cm/H20 after 6 months, to 21.2 after 12 months and to 23.8 after 24 months. There was no post voiding residual urine 2 days after treatment in all patients. Follow-up shows transurethral electrovaporization of the prostate is an efficient and safe technique for treatment of BPH.

Original languageEnglish
Pages (from-to)149-153
Number of pages5
JournalArchivio Italiano di Urologia e Andrologia
Issue number3
Publication statusPublished - Jun 1999


ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this